Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07229729
PHASE2

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.

Official title: A Randomized, Open-label, Multicenter Phase II Clinical Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2025-11-24

Completion Date

2029-10

Last Updated

2025-12-01

Healthy Volunteers

No

Interventions

DRUG

SHR-A2102

SHR-A2102.

DRUG

Adebrelimab

Adebrelimab.

DRUG

Paclitaxel

Paclitaxel.

DRUG

Carboplatin

Carboplatin.

DRUG

Alomnertinib Mesilate

Alomnertinib Mesilate.

DRUG

Furmonertini Mesilate

Furmonertini Mesilate.

DRUG

Osimertinib Mesylate

Osimertinib Mesylate.

Locations (1)

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China